

PRABHA IAS IPS COACHING ACADEMY



Biopharma SHAKTI Initiative:

Recent - India, which is already known as the “Pharmacy of the World” for generic medicines, Biopharma SHAKTI aims to extend this leadership into the high-value biologics and biosimilars segment.

Launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, with an outlay of ₹10,000 crore for five years (2026–31).

Aims to launch 100 biologics by 2047, supporting the goals of Viksit Bharat and Swasth Bharat. Biologics are expected to account for nearly 40% of global prescription drugs by 2031.

Supported by schemes such as the PRIP Scheme, National Biopharma Mission, and BIRAC programs.

Biopharmaceuticals: Biotechnology-based medicines produced using living organisms.

Biologics: Complex medicines derived from living cells (e.g., vaccines, insulin, monoclonal antibodies). Sub-set of Biopharmaceuticals.

Biosimilars: Highly similar, lower-cost versions of approved biologic medicines.